Digital Event Horizon
NVIDIA Revolutionizes Healthcare with Domain-Expert Agentic AI
NVIDIA is pushing the boundaries of artificial intelligence in healthcare by collaborating with leading institutions to develop cutting-edge agentic AI solutions. From clinical trials to genomic research and pathology, NVIDIA's expertise is driving innovation and transforming the way we approach biomedical science and patient care.
NVIDIA collaborates with healthcare institutions to develop cutting-edge agentic AI solutions. The partnership aims to boost efficiency in clinical trials and optimize planning for therapy launches. IQVIA, Illumina, and Mayo Clinic are leveraging NVIDIA's agentic AI capabilities for various applications. NVIDIA provides multiyear funding for researchers to focus on innovative research instead of grant writing. The company announces new resources for healthcare and life sciences developers, including an NVIDIA NIM microservice and BioNeMo Blueprint. A new physical AI platform called NVIDIA Cosmos is unveiled, featuring state-of-the-art generative world foundation models.
NVIDIA, the leading innovator in artificial intelligence (AI) and high-performance computing, recently collaborated with esteemed healthcare institutions to develop cutting-edge agentic AI solutions. These innovative projects have the potential to transform biomedical research, clinical trials, and pathology by leveraging NVIDIA's expertise in domain-expert agentic AI.
The partnership between NVIDIA and IQVIA, a leading clinical research and commercial services provider, aimed to boost the efficiency of clinical trials and optimize planning for the launch of therapies and medical devices. IQVIA is working with NVIDIA to build custom foundation models and agentic AI workflows trained on the organization's vast healthcare-specific information and deep domain expertise.
According to Ari Bousbib, chairman and CEO of IQVIA, "The opportunity here is to try to reduce the dependencies and sequential series of steps that require a lot of interactions, and handle them without human touch. AI agents will be able to eliminate the white space, that is, the time waiting for humans to complete those tasks. There's a great opportunity to reduce time and costs."
Meanwhile, Illumina, a DNA sequencing technology leader, is utilizing NVIDIA's agentic AI capabilities to enhance genomic research and develop new solutions for disease diagnosis. Jacob Thaysen, CEO of Illumina, noted that "Combining other information, other modalities, other 'omics'...is going to give us much deeper insight into biology. But while DNA was very difficult itself, when you then combine all the omics, it becomes exponentially more challenging."
Mayo Clinic, one of the world's leading research hospitals, is also leveraging NVIDIA's technology to transform cancer care with AI insights. Christina Zorn, chief administrative officer at Mayo Clinic, shared that "We saw a paradigm shift in healthcare. You're either going to disrupt from within or you're going to be disrupted. We knew we had to embrace tech in a way that was really going to optimize everything we do."
The partnership between NVIDIA and the Arc Institute nonprofit research organization aims to advance drug discovery through AI innovation. Patrick Collison, cofounder of Stripe, emphasized the importance of providing multiyear funding for researchers to focus on innovative research instead of grant writing.
"A lot of the low-hanging fruit, the stuff that is easier to discover, we did," Collison said, referring to the development of groundbreaking treatments like antibiotics, chemotherapy, and more in decades past. "Today, it's immensely harder."
NVIDIA also announced new resources for healthcare and life sciences developers, including an NVIDIA NIM microservice for GenMol, a generative AI model for controlled, high-performance molecular generation — and an NVIDIA BioNeMo Blueprint for protein binder design, part of the NVIDIA Blueprints collection of enterprise-grade reference workflows for agentic and generative AI use cases.
To support the development of these AI models, NVIDIA recently unveiled NVIDIA Cosmos, a physical AI platform that includes state-of-the-art generative world foundation models. These models apply the same technique as a language model that predicts the next word in a sentence — instead predicting the next action a robot should take.
"The idea that you can generate the next frame for a video has become common sense," said Jensen Huang, NVIDIA founder and CEO. "And if that's the case, is it possible that generating the next articulation could be common sense? And the answer is absolutely."
The future of AI in healthcare promises to involve agentic AI models that are capable of reasoning and problem-solving. By deploying foundation models to narrow the field of potential drug molecules and streamlining workflows with agentic AI, these innovators are helping meet the global demand for patient care.
Healthcare has a more severe labor shortage than any other field — the industry is expected to be short 10 million workers by the end of the decade, according to the World Health Organization. By deploying foundation models to narrow the field of potential drug molecules and streamlining workflows with agentic AI, these innovators are helping meet the global demand for patient care.
Related Information:
https://blogs.nvidia.com/blog/jp-morgan-healthcare-2025/
https://nvidianews.nvidia.com/news/nvidia-partners-with-industry-leaders-to-advance-genomics-drug-discovery-and-healthcare
Published: Wed Jan 15 01:08:41 2025 by llama3.2 3B Q4_K_M
